Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01887886 · ClinicalTrials.gov registry record · Phase 3
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
A Phase 3 study of Non-squamous Non-small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
- 20
- Study locations
NCT01887886: Completed Phase 3 study of Non-squamous Non-small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
NCT01887886 is a Phase 3 study of Non-squamous Non-small Cell Lung Cancer that has completed, run by Hoffmann-La Roche. The registered enrollment target is 10 participants, below the 397-participant average among 9 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01887886, a Phase 3 study of Non-squamous Non-small Cell Lung Cancer, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
- 20
- Study locations
Study Summary
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of onartuzumab in combination with erlotinib in patients with previously untreated, unresectable stage IIIB or IV non-small cell lung cancer identified to carry and activating EGFR mutation and MET-positive. Patients will be randomized to receive either onartuzumab 15 mg/kg intravenously every 3 weeks in combination with erlotinib 150 mg orally daily or placebo in combination with erlotinib. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Conditions Studied
Interventions
- DRUG placebo
- DRUG erlotinib
- DRUG onartuzumab
Study Locations (20)
California
- - Bakersfield
- - Fullerton
- - Long Beach
- - Los Angeles
- - Los Angeles
- - San Luis Obispo
Other
- - Caen
- - Lyon
- - Nantes
- - Großhansdorf
- - Oldenburg
Florida
- - Fort Myers
- - Orlando
- - St. Petersburg
Louisiana
- - Marrero
- - Metairie
Illinois
- - Chicago
Missouri
- - St Louis
Ohio
- - Canton
Tennessee
- - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
What the finished NCT01887886 record still lists
NCT01887886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 397-participant average among 9 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Non-squamous Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT01887886 names 20 study sites across 8 states, led by California, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT01887886 about?
NCT01887886 is a clinical study titled "A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation". This multicenter, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of onartuzumab in combination with erlotinib in patients with previously untreated, unresectable stage IIIB or IV non-small cell lung cancer identified to carry and activating EGFR mutation and...
What is the current status of trial NCT01887886?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2013-12. Estimated completion is 2015-02.
What conditions does trial NCT01887886 study?
This clinical trial studies the following conditions: Non-squamous Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT01887886?
The interventions under investigation include: placebo (DRUG), erlotinib (DRUG), onartuzumab (DRUG).
Who is sponsoring clinical trial NCT01887886?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01887886 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Louisiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-squamous Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01887886's enrollment target sits among peer trials
10 10th of 9 the lowest of 9 other Non-squamous Non-small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-squamous Non-small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
RECRUITING · Phase 3
-
Phase III Study of AK112 for NSCLC Patients
ACTIVE NOT RECRUITING · Phase 3
-
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
COMPLETED · Phase 3
-
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia